
Bioequivalence and Biowaiver study
Bioequivalence is a term in pharmacokinetics used to assess the expected in vivo biological equivalence of two proprietary preparations of a drug. If two products are said to be bioequivalent it means that they would be expected to be, for all intents and purposes, the same. – A Biowaiver means that in vivo bioavailability and/or bioequivalence studies may be waived (not considered necessary for product approval). Instead of conducting expensive and time consuming in vivo studies, a dissolution test could be adopted as the surrogate basis for the decision as to whether the two pharmaceutical products are equivalent. – MSA bioequivalence center have all facilities and equipment required to undergo steps of Biowaiver and Bioequivalence study
Analytical Research
Research Service support and enhance the research, education, and public service missions of the University by providing access to characterization and process instrumentation. – Staff provides the assistance and guidance necessary so that students, faculty, and industry get the most effective and appropriate use of the center’s facilities.
Bioequivalence Center - Contacts
- 26 July Mehwar Road intersection with Wahat Road, 6th October City. Egypt.
- Tel. : (+202) 38371534-5-7/ Ext: 5146
- becenter@msa.edu.eg
- Hotline : 16672
- Center Manager: Dr. Dina Karam +0201129801960
- QA Manager: Dr. Aya Badr +0201112006907